CCDC129 Inhibitors
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent kinase inhibitor, which can interfere with various kinases that phosphorylate CCDC129. Phosphorylation is critical for the functional regulation of many proteins, hence, staurosporine indirectly inhibits CCDC129 function by preventing its phosphorylation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that blocks the PI3K/AKT signaling pathway. Since PI3K can regulate protein function through various downstream targets, inhibition of this pathway can result in reduced phosphorylation and activation of proteins such as CCDC129. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin specifically inhibits mTOR (mammalian target of rapamycin), which is part of the mTOR signaling pathway involved in cell growth and protein synthesis. Inhibition of mTOR can lead to a decrease in the overall protein synthesis rate, potentially reducing the levels of CCDC129. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a MEK inhibitor that disrupts the MAPK/ERK pathway. Since the MAPK/ERK pathway can modulate various cellular functions, including protein expression and activity, the inhibition of this pathway may indirectly decrease the activity of CCDC129. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. The p38 MAPK pathway is implicated in the regulation of protein synthesis and modification. Its inhibition can lead to decreased activation of proteins that are regulated by this pathway, including potentially CCDC129. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor similar to LY294002, and it acts by inhibiting the AKT signaling pathway. By blocking this pathway, the phosphorylation and subsequent activation of proteins involved in this pathway, such as CCDC129, can be indirectly inhibited. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of MEK, which is a part of the MAPK/ERK pathway. By inhibiting MEK, PD98059 can reduce the activation of downstream proteins in this pathway, potentially leading to a decrease in the functional activity of CCDC129. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK (c-Jun N-terminal kinase), part of the MAPK signaling pathways. Inhibition of JNK affects the phosphorylation state of target proteins, which could include CCDC129, thereby decreasing its activity. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor that can prevent the degradation of regulatory proteins that control the cell cycle, apoptosis, and other critical cellular processes. This can result in the altered regulation of proteins like CCDC129. | ||||||
ZM-447439 | 331771-20-1 | sc-200696 sc-200696A | 1 mg 10 mg | $153.00 $356.00 | 15 | |
ZM-447439 is an Aurora kinase inhibitor, which interferes with the cell cycle and division. Aurora kinases can phosphorylate various substrates, and their inhibition may reduce the phosphorylation and activity of proteins like CCDC129. | ||||||